



**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington D.C. 20549

FORM 20-F

- REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal
year ended December 31, 2011
OR
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
 SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 1-15024

NOVARTIS AG

(Exact name of Registrant as specified in its charter)

NOVARTIS Inc.

(Translation of Registrant's name into English)

Switzerland

(Jurisdiction of incorporation or organization)

Lichtstrasse 35

4056 Basel, Switzerland

(Address of principal executive offices)

Felix R. Ehrat

Group General Counsel

Novartis AG

CH-4056 Basel

Switzerland

011-41-61-696-9511

felix.ehrat@novartis.com

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of class</u>	<u>Name of each exchange on which registered</u>
American Depositary Shares each representing 1 share, nominal value CHF 0.50 per share, and shares	New York Stock Exchange, Inc.

Securities registered or to be registered pursuant to Section 12(g) of the Act:

None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

None

Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report:

2,406,693,857 shares

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP International Financial Reporting Standards as issued by the International Accounting Standards Board Other

If "Other" has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow.

Item 17 Item 18

TABLE OF CONTENTS

INTRODUCTION AND USE OF CERTAIN TERMS	1
FORWARD LOOKING STATEMENTS	1
PART I	3
Item 1. Identity of Directors, Senior Management and Advisers	3
Item 2. Offer Statistics and Expected Timetable	3
Item 3. Key Information	3
3.A Selected Financial Data	3
3.B Capitalization and Indebtedness	6
3.C Reasons for the offer and use of proceeds	6
3.D Risk Factors	6
Item 4. Information on the Company	17
4.A History and Development of Novartis	17
4.B Business Overview	20
Pharmaceuticals	22
Alcon	54
Sandoz	62
Vaccines and Diagnostics	68
Consumer Health	75
4.C Organizational Structure	78
4.D Property, Plants and Equipment	78
Item 4A. Unresolved Staff Comments	85
Item 5. Operating and Financial Review and Prospects	85
5.A Operating Results	85
5.B Liquidity and Capital Resources	159
5.C Research & Development, Patents and Licenses	164
5.D Trend Information	165
5.E Off-Balance Sheet Arrangements	165
5.F Aggregate Contractual Obligations	165
Item 6. Directors, Senior Management and Employees	166
6.A Directors and Senior Management	166
6.B Compensation	174
6.C Board Practices	199
6.D Employees	219
6.E Share Ownership	219
Item 7. Major Shareholders and Related Party Transactions	220
7.A Major Shareholders	220
7.B Related Party Transactions	221
7.C Interests of Experts and Counsel	222
Item 8. Financial Information	222
8.A Consolidated Statements and Other Financial Information	222
8.B Significant Changes	222
Item 9. The Offer and Listing	223
9.A Listing Details	223
9.B Plan of Distribution	224
9.C Market	224
9.D Selling Shareholders	224
9.E Dilution	224
9.F Expenses of the Issue	224
Item 10. Additional Information	224
10.A Share Capital	224
10.B Memorandum and Articles of Association	224
10.C Material Contracts	228

10.D	Exchange Controls	228
10.E	Taxation	228
10.F	Dividends and Paying Agents	233
10.G	Statement by Experts	233
10.H	Documents on Display	233
10.I	Subsidiary Information	233
Item 11.	Quantitative and Qualitative Disclosures about Non-Product-Related Market Risk . .	234
Item 12.	Description of Securities other than Equity Securities	238
12.A	Debt Securities	238
12.B	Warrants and Rights	238
12.C	Other Securities	238
12.D	American Depositary Shares	239
PART II.	240
Item 13.	Defaults, Dividend Arrearages and Delinquencies	240
Item 14.	Material Modifications to the Rights of Security Holders and Use of Proceeds	240
Item 15.	Controls and Procedures	240
Item 16A.	Audit Committee Financial Expert	240
Item 16B.	Code of Ethics	240
Item 16C.	Principal Accountant Fees and Services	241
Item 16D.	Exemptions from the Listing Standards for Audit Committees	242
Item 16E.	Purchases of Equity Securities by the Issuer and Affiliated Purchasers	242
Item 16F.	Change in Registrant's Certifying Accountant	242
Item 16G.	Corporate Governance	243
PART III	244
Item 17.	Financial Statements	244
Item 18.	Financial Statements	244
Item 19.	Exhibits	245

INTRODUCTION

Novartis AG and its consolidated affiliates (Novartis or the Group) publish consolidated financial statements expressed in US dollars. Our consolidated financial statements found in Item 18 of this annual report on Form 20-F (Form 20-F) are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).

USE OF CERTAIN TERMS

In this Form 20-F, references to “US dollars,” “\$” or “\$” are to the lawful currency of the United States of America, and references to “CHF” are to Swiss francs; references to the “United States” or to “US” are to the United States of America, references to the European Union (EU) are to the European Union and its 27 member states and references to “Americas” are to North, Central (including the Caribbean) and South America, unless the context otherwise requires; references to “associates” are to employees of our affiliates; references to the “FDA” are to the US Food and Drug Administration, references to “EMA” are to the European Medicines Agency, an agency of the EU, and references to the CHMP are to the EMA’s Committee for Medicinal Products for Human Use; references to “ADS” or “ADSs” are to Novartis American Depositary Shares, and references to “ADR” or “ADRs” are to Novartis American Depositary Receipts; references to the NYSE are to the New York Stock Exchange, and references to the SIX are to the SIX Swiss Exchange. All product names appearing in italics are trademarks owned by or licensed to Group companies. Product names identified by a “®” or a “™” are trademarks that are not owned by or licensed to Group companies. You will find the words “we,” “our,” “us” and similar words or phrases in this Form 20-F. We use those words to comply with the requirement of the US Securities and Exchange Commission to use “plain English” in public documents like this Form 20-F. For the sake of clarification, each Group company is legally separate from all other Group companies and manages its business independently through its respective board of directors or other top local management body. No Group company operates the business of another Group company nor is any Group company the agent of any other Group company. Each executive identified in this Form 20-F reports directly to other executives of the Group company which employs the executive, or to that Group company’s board of directors.

FORWARD LOOKING STATEMENTS

This Form 20-F contains certain “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which can be identified by terminology such as “planned,” “expected,” “will,” “potential,” “pipeline,” “outlook,” or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products; or regarding potential future sales or earnings of the Novartis Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for any existing products in any market, or that any approvals which are obtained will be obtained at any particular time, or that any such products will achieve any particular revenue levels. Nor can there be any guarantee that the Group, or any of its divisions, will achieve any particular financial results. In particular, management’s expectations could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, including the potential outcomes of our ongoing discussions with health authorities concerning *Rasilez/Tekturna* as a result of the ALTITUDE study, and including the outcome of health authority reviews of the benefits and risks of *Gilenya*; unexpected clinical trial results, including additional analyses of existing clinical data or unexpected new clinical data, including any potential new analyses of the ALTITUDE study which may occur; the Group’s ability to obtain or maintain patent or other proprietary intellectual property protection, including the ultimate extent of the impact on the Group of the loss of patent protection on key products which commenced last year and will continue this year; unexpected product manufacturing issues, including the potential outcomes of the Warning Letter issued to us with respect to three Sandoz manufacturing facilities, and the potential outcome of the shutdown of the OTC manufacturing facility at Lincoln, Nebraska; government, industry, and general public pricing pressures; uncertainties regarding actual or potential legal proceedings, including, among others, actual or potential product liability litigation, litigation regarding sales and marketing practices, shareholder litigation, government investigations and intellectual property disputes; competition in general; uncertainties regarding the

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.